A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant

You may be eligible if

• DISEASE CHARACTERISTICS:
• Metastatic melanoma that is HLA-A2 positive.
• No primary melanoma of ocular or mucosal origin.
• Measurable or resected metastatic disease required.
• PRIOR/CONCURRENT THERAPY:
• BIOLOGIC THERAPY: No prior (greater than 30 days) or concurrent Biologic Therapy.
• CHEMOTHERAPY: No prior (greater than 30 days) or concurrent chemotherapy.
• ENDOCRINE THERAPY: No prior (greater than 30 days) or concurrent hormone therapy.
• No requirement for steroids.
• RADIOTHERAPY: No prior (greater than 30 days) or concurrent radiotherapy.
• SURGERY: Not specified.
• PATIENT CHARACTERISTICS:
• Age: 18 and over.
• Performance Status: ECOG 0 or 1.
• Life Expectancy: More than 3 months.
• HEMATOPOIETIC: No coagulation disorder.
• HEPATIC:
• Bilirubin no greater than 2.0 mg/dL.
• No Hepatitis BsAg antibody.
• RENAL: Creatinine no greater than 2.0 mg/dL.
• CARDIOVASCULAR: No major cardiovascular illness.
• PULMONARY: No major respiratory illness.
• OTHER:
• No previous allergic reaction to incomplete Freund's adjuvant.
• HIV negative.
• No active systemic infection.
• Not pregnant or lactating.